Form 4: Tandem Diabetes Officer Reports RSU Vesting, Tax Withholding

Mark D. Novara, EVP & Chief Commercial Officer of Tandem Diabetes Care, reported the vesting of restricted stock units and subsequent tax withholding.

Summary

• Mark D. Novara, Executive Vice President & Chief Commercial Officer of Tandem Diabetes Care Inc. (TNDM), reported transactions on November 17, 2025.
• 76 shares of common stock were acquired by Mr. Novara upon the vesting of Restricted Stock Units (RSUs).
• 40 shares of common stock were withheld by Tandem Diabetes Care Inc. to satisfy tax withholding requirements related to the RSU vesting, at a price of $18.61 per share.
• Following these transactions, Mr. Novara directly owns 32,384 shares of common stock.
• Mr. Novara also beneficially owns 457 Restricted Stock Units, which represent a contingent right to receive either one share of common stock or cash in lieu thereof.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is routine for executive compensation, showing the executive realizing value from past awards and maintaining significant ownership. The tax withholding is a standard procedure and does not indicate negative sentiment.

Positives

• The vesting of 76 Restricted Stock Units indicates a portion of executive compensation is being realized, aligning executive interests with shareholder value.
• The executive's direct beneficial ownership of common stock remains substantial at 32,384 shares, demonstrating continued alignment with shareholder interests.

Negatives

• 40 shares were disposed of to cover tax liabilities, representing a reduction in direct share ownership, although this is a standard procedure for RSU vesting.

Future Outlook

The remaining 457 Restricted Stock Units will vest in eight equal quarterly installments following the initial 33% vesting on May 15, 2025, indicating future share acquisitions for the executive.

Industry Context

This insider transaction report reflects standard executive compensation practices within publicly traded companies, where equity awards like Restricted Stock Units are used to incentivize and retain key management personnel. It does not provide specific insights into broader industry trends.

Comparison to Industry Standards

• The RSU vesting and tax withholding transactions are standard practices for executive compensation in publicly traded companies, aligning executive incentives with long-term shareholder value.
• The specific terms of the 2023 Long-Term Incentive Plan, under which these RSUs were awarded, are consistent with typical equity compensation plans observed in the medical device and biotechnology sectors.

Stakeholder Impact

• Shareholders: The transaction reflects a standard executive compensation event, aligning executive interests with long-term company performance through equity ownership.
• Employees: The RSU vesting demonstrates the company's commitment to its long-term incentive plan for executives.

Next Steps

• Future vesting of the remaining 457 Restricted Stock Units in eight equal quarterly installments after May 15, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and subsequent tax withholding. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is a standard part of executive compensation and reflects the executive realizing value from previously granted equity awards while maintaining a substantial ownership stake. Therefore, a 'hold' recommendation is appropriate as there are no new fundamental drivers for a 'buy' or 'sell' decision based solely on this filing.

Keywords

Tandem Diabetes Care, TNDM, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Stock Ownership, Mark D. Novara